Acetyl-L-Carnitine Deficiency in Patients with Major Depressive Disorder
- Description
This study identified biological targets in major depressive disorder (MDD). Acetyl-l-carnitine (LAC), which is critical for hippocampal function and several behavioral domains, has rapid and enduring antidepressant like effects in LAC deficient rodents. As a result, this study examined LAC levels in humans. Following an initial phone screen, potential participants were evaluated in person to determine study eligibility. The age range of participants were between 20 and 70 years. Clinical assessment consisted of a physical examination, including measures of height, weight, and body mass index (BMI). They also collected data on current medication use, history of failed antidepressant trials, and demographic information. This study found that LAC levels were decreased in patients with MDD, which suggest that LAC may serve as a biomarker for MDD.
Access
- Restrictions
-
Application RequiredAuthor Approval Required
- Instructions
- Please complete the Data Request Form to request access to this dataset. The information included in the form will be sent to the Corresponding Author who will evaluate your request for their data. The Corresponding Author may ask you to provide additional information if necessary.
- Grant Support
-
Hope for Depression Research Foundation/Hope for Depression Research FoundationRobertson Foundation/Robertson FoundationPritzker Neuropsychiatric Disorders Research Consortium/Pritzker Neuropsychiatric Disorders Research Consortium